Sort
11,323 grants matching “glioblastoma”
Targeting Mechanisms of Acquired Temozolomide Resistance in Glioblastoma
$336,875Clark Chin-Chung Chen · University Of Minnesota · R01 · FY2019 · NS
Targeting the cholesterol metabolism to treat glioblastoma
$336,784Deliang Guo · Ohio State University · R01 · FY2013 · NS
Developing therapeutic strategies to elicit metabolic synthetic lethality in glioblastoma
$336,769Prakash Chinnaiyan · William Beaumont Hospital Research Inst · R01 · FY2021 · NS
OV therapy induced changes in tumor secretome and their impact on therapy
$336,602Balveen Kaur · Ohio State University · R01 · FY2014 · NS
Molecular Targeting of L1CAM to Inhibit Glioblastoma Stem Cell Invasion
$336,569Shideng Bao · Cleveland Clinic Lerner Com-Cwru · R01 · FY2012 · NS
Combination therapy to inhibit glioma growth by Ad MMP2 and radiation
$336,569Jasti S Rao · University Of Illinois At Chicago · R01 · FY2012 · NS
Molecular Targeting of L1CAM to Inhibit Glioblastoma Stem Cell Invasion
$336,569Shideng Bao · Cleveland Clinic Lerner Com-Cwru · R01 · FY2011 · NS
Combination therapy to inhibit glioma growth by Ad MMP2 and radiation
$336,569Jasti S Rao · University Of Illinois At Chicago · R01 · FY2011 · NS
Regulation and Function of Ascl1 (Mash1) in Neural Development
$336,569Jane E Johnson · Ut Southwestern Medical Center · R01 · FY2011 · NS
Project 2 - Clinical translation
$336,548Robert A Gatenby · H. Lee Moffitt Cancer Ctr & Res Inst · U54 · FY2017 · CA
Contributions of Akt to Glioblastoma Formation
$336,532University Of California San Francisco · R01 · FY2003 · CA
IDO1 and Immunotolerance in Glioblastoma
$336,419Derek Alan Wainwright · Northwestern University At Chicago · R01 · FY2017 · NS
The role of mTORC2 in reprogramming cancer cell metabolism
$336,412Paul S Mischel · Ludwig Institute For Cancer Res Ltd · R01 · FY2018 · NS
The role of mTORC2 in reprogramming cancer cell metabolism
$336,412Paul S Mischel · Ludwig Institute For Cancer Res Ltd · R01 · FY2019 · NS
Cytoplasmic Multimerization of the RNA-binding protein HuR is Oncogenic in Glioma
$336,380Louis B Nabors · University Of Alabama At Birmingham · R01 · FY2017 · CA
The Role of CK2 in Glioblastoma Development
$336,263Etty N. Benveniste · University Of Alabama At Birmingham · R01 · FY2020 · CA
The Role of CK2 in Glioblastoma Development
$336,263Etty N. Benveniste · University Of Alabama At Birmingham · R01 · FY2018 · CA
IDO1 and Immunotolerance in Glioblastoma
$336,225Derek Alan Wainwright · Northwestern University At Chicago · R01 · FY2018 · NS
Design of Therapeutic Strategies Specific for Breast Cancer Initiating Cells
$336,150Germana Rappa · Nevada Cancer Institute · R01 · FY2010 · CA
Rho- and GPCR-mediated signaling through novel cellular effectors
$336,038Joan Heller Brown · University Of California, San Diego · R01 · FY2009 · GM
Cellular Pharmacology of Rapamycin
$336,000Burnham Institute For Medical Research · R01 · FY2005 · CA
Cellular Pharmacology of Rapamycin
$336,000Burnham Institute For Medical Research · R01 · FY2004 · CA
Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas
$336,000Thomas C Chen · Neonc Technologies, Inc. · R41 · FY2020 · CA
Cellular Pharmacology of Rapamycin
$336,000Burnham Institute For Medical Research · R01 · FY2003 · CA
New Vectors and Delivery Systems for Glioblastoma Therapy
$335,897Xandra Owens Breakefield · Massachusetts General Hospital · P01 · FY2009 · CA